Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Unknown 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 16Nasopharyngeal Carcinoma 7Breast Neoplasms 4Uterine Cervical Neoplasms 3Nasopharyngeal Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Recurrence 2Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Squamous Non-small Cell Lung Cancer 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Solid Tumors 1Sarcoma 1Optic Nerve Glioma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neuroblastoma 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma, T-Cell 1Locally Advanced Squamous Non-small Cell Lung Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Cancer Organoids 1Advanced Pancreatic Cancer 1

Interventions

Carboplatin 177Radiotherapy 139Cisplatin 110Pemetrexed 102Docetaxel 93Paclitaxel 92Gemcitabine 78Erlotinib Hydrochloride 73Magnetic Resonance Spectroscopy 72Radiosurgery 67Bevacizumab 65pembrolizumab 64Etoposide 60Blood Specimen Collection 60durvalumab 53Specimen Handling 48Nivolumab 48Surveys and Questionnaires 47Drug Therapy 41Standard of Care 35Radiation 33osimertinib 32atezolizumab 32Surgical Procedures, Operative 30Topotecan 29Irinotecan 29Gefitinib 29Educational Status 29Early Intervention, Educational 29Biopsy 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lung Neoplasms × Endostatins × Clear all
NCT04613284 2020-11-03

RELIEF

Shanghai Chest Hospital

Phase 4 Unknown
97 enrolled
Thoracic

Lung Neoplasms

NCT02375022 2015-03-24

Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations

Zhejiang University

Phase 2 Unknown
10 enrolled
Thoracic

Lung Neoplasms

NCT02350361 2015-01-29

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Peking University Third Hospital

Phase 2/3 Unknown
60 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡